Story perspectives

FDA Cracks Down on Telehealth Firms Over Misleading Drugs

9/19/2025

37 3

Summary

Story summary

Federal health officials are targeting telehealth companies for promoting unapproved prescription drugs, particularly weight loss medications.
The FDA issued over 100 warning letters, including to Hims & Hers, for misleading claims about compounded products.
Hims claimed its products matched the active ingredients of FDA-approved drugs like Ozempic and Wegovy, which the FDA disputed.
This action marks the FDA's first direct intervention against online drug advertising.
Regulators criticized Eli Lilly and Novo Nordisk for a misleading infomercial featuring Oprah Winfrey.

1 of 1

Story summary

Federal health officials are targeting telehealth companies for promoting unapproved prescription drugs, particularly weight loss medications.
The FDA issued over 100 warning letters, including to Hims & Hers, for misleading claims about compounded products.
Hims claimed its products matched the active ingredients of FDA-approved drugs like Ozempic and Wegovy, which the FDA disputed.
This action marks the FDA's first direct intervention against online drug advertising.
Regulators criticized Eli Lilly and Novo Nordisk for a misleading infomercial featuring Oprah Winfrey.